Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BRD3308 is a highly selective inhibitor of HDAC3(IC50 of 54 nM), attenuating PE-mediated phosphorylation of ERK but not JNK.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 38.00 | |
2 mg | In stock | $ 54.00 | |
5 mg | In stock | $ 87.00 | |
10 mg | In stock | $ 128.00 | |
25 mg | In stock | $ 233.00 | |
50 mg | In stock | $ 352.00 | |
100 mg | In stock | $ 528.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 97.00 |
Description | BRD3308 is a highly selective inhibitor of HDAC3(IC50 of 54 nM), attenuating PE-mediated phosphorylation of ERK but not JNK. |
Targets&IC50 | HDAC1:1260 nM , HDAC1:5100 nM (Ki) , HDAC3:29 nM (Ki) , HDAC3:54 nM , HDAC2:1340 nM , HDAC2:6300 nM (Ki) |
In vivo | BRD3308 is a selective HDAC3 inhibitor,to reduce hyperglycaemia and increase insulin secretion in a rat model of type 2 diabetes.?At diabetes onset, an ambulatory hyperglycaemic clamp was performed.?HDAC3 inhibition improved hyperglycaemia over the study period without affecting weight gain.?At the end of the hyperglycaemic clamp, circulating insulin levels were significantly higher in BRD3308-treated rats.?Pancreatic insulin staining and contents were also significantly higher.?These findings highlight HDAC3 as a key therapeutic target for β-cell protection in type 2 diabetes[1]. |
Animal Research | Male Zucker Diabetic Fatty (Obese) rats (6-week-old); 5 mg/kg; Intraperitoneal injection; every second day |
Molecular Weight | 287.29 |
Formula | C15H14FN3O2 |
CAS No. | 1550053-02-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 52 mg/ml(181 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BRD3308 1550053-02-5 Apoptosis Chromatin/Epigenetic DNA Damage/DNA Repair Microbiology/Virology Proteases/Proteasome HIV Protease HDAC β-cells glucolipotoxicity inflammatory Human immunodeficiency virus Histone deacetylases HDAC3 diabetes HIV-1 Inhibitor latency BRD 3308 cytokines hyperglycaemia HIV inhibit insulin BRD-3308 inhibitor